Search clinical trials for: Endocrine therapy

Total 20184 results

Ottawa Hospital Research Institute

Recruiting

Evaluating Harms and Benefits of Endocrine Therapy in Patients ≥70 Years of Age With Lower Risk Breast Cancer

Breast Cancer

Canada
Ottawa Hospital Research Institute

Completed

Evaluating the Dose Timing (Morning vs Evening) of Endocrine Therapy and Its Effects on Tolerability and Compliance

Breast Cancer

Canada
Second Affiliated Hospital, School of Medicine,...

Recruiting

Application of Radiomics in Breast Cancer

Breast Cancer | Elastography | Ultrasound | Radiomics | Pathology

China
The Third Xiangya Hospital of Central South University

Not yet recruiting

TUPKRP Combined With MAB Therapy for LUTS/PCa

Quality of Life | Lower Urinary Tract Symptoms | Advanced Prostate Cancer | Overall Survival | Progression of Prostate Cancer
ETOP IBCSG Partners Foundation
Alliance for Clinical Trials in Oncology; Canadian Cancer Trials Group; Breast...

Active, not recruiting

Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer (POSITIVE)

Early Breast Cancer

Korea, Republic of, United States, France, Canada, Spain, Lebanon, Belgium, Switzerland, Israel, Ireland, Japan, Italy, Denmark, Austria, Australia, Greece, Hungary, Netherlands, Norway, Portugal, Serbia, Slovenia
Haruhiko Fukuda
Ministry of Health, Labour and Welfare, Japan

Completed

Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy

Prostate Cancer

Japan
Dana-Farber Cancer Institute

Not yet recruiting

INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy

Breast Cancer | Breast Carcinoma | Breast Cancer Female

United States
Pfizer

Active, not recruiting

A Study of PF-06873600 in People With Cancer

HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer

United States, Japan, Canada, Russian Federation, Bulgaria, Ukraine
Swiss Group for Clinical Cancer Research
The Belgian Society of Medical Oncology

Terminated

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

Breast Cancer

Switzerland, Belgium, Austria
Institut Curie
Zionexa

Recruiting

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients (ECLECTIC)

Breast Carcinoma

France
University of Michigan Rogel Cancer Center
Johns Hopkins University; Memorial Sloan Kettering Cancer Center; University... and other collaborators

Active, not recruiting

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

Breast Neoplasms

United States
Novartis Pharmaceuticals

Active, not recruiting

A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment (RIBANNA)

Breast Cancer

Germany
Ottawa Hospital Research Institute

Recruiting

Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance (REaCT-TEMPO)

Breast Cancer

Canada
Mayo Clinic

Recruiting

Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer

Breast Cancer | Residual

United States
Novartis Pharmaceuticals
Translational Research in Oncology

Active, not recruiting

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE)

Early Breast Cancer

United States, Belgium, Canada, Italy, United Kingdom, Hungary, Taiwan, Australia, Germany, Spain, Austria, Russian Federation, Korea, Republic of, China, France, Brazil, Ireland, Argentina, Romania, Poland
M.D. Anderson Cancer Center

Active, not recruiting

Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

Breast Cancer

United States
Washington University School of Medicine
Biovica

Not yet recruiting

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

Metastatic Breast Cancer | Unresectable Breast Cancer

United States
Massachusetts General Hospital
Novartis

Recruiting

CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer (LEADER)

Breast Cancer

United States
Eli Lilly and Company
NSABP Foundation Inc

Active, not recruiting

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)

Breast Cancer

United States, Spain, China, Germany, Taiwan, United Kingdom, Canada, Singapore, Italy, Australia, Japan, Hungary, Russian Federation, Belgium, New Zealand, Austria, India, Saudi Arabia, France, Czechia, Korea, Republic of, Finland, Argentin... and more
Istituto Scientifico Romagnolo per lo Studio e...
Agenzia Italiana del Farmaco

Unknown

CDK4/6-inhibitor or Chemotherapy, in Combination With ENDOcrine Therapy, for Advanced Breast Cancer / KENDO (KENDO)

Metastatic Breast Cancer | Hormone Receptor Positive Breast Cancer | Hormone Receptor Negative Breast Cancer

Italy
Philipps University Marburg Medical Center

Unknown

Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer

Female Breast Cancer

Germany
Henan Cancer Hospital

Recruiting

Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer

Breast Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

Early Breast Cancer

China
Region Örebro County
Helsinki University Central Hospital; Hospital Clinic of Barcelona; University... and other collaborators

Recruiting

Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients (IMPORTANT)

Quality of Life | Advanced Breast Cancer | Metastatic Breast Cancer | Toxicity | Older Patients

Sweden, Finland, Greece, Italy, Norway, Spain
Shengjing Hospital

Recruiting

Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy

Breast Cancer

China
CCTU- Cancer Theme
Breast Cancer Now; CRUK Cambridge Institute

Recruiting

Neo-RT: A Study Investigating Whether Changing the Sequence of Treatments (Starting Radiotherapy Followed by Hormone Therapy Before Surgery) is Feasible (Neo-RT)

Breast Cancer

United Kingdom
Prof. W. Janni

Completed

DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs (DETECT III)

HER2-negative Metastatic Breast Cancer | HER2-positive Circulating Tumor Cells

Germany
Novartis Pharmaceuticals

Recruiting

A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia (PROSPERITY)

Breast Cancer

Russian Federation
Peking Union Medical College Hospital

Not yet recruiting

Young Patients With Early Breast Cancer

Breast Cancer Female
European Organisation for Research and Treatment...
Hoffmann-La Roche; UNICANCER; Janssen Diagnostics, LLC; SUCCESS

Completed

Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer (TREAT-CTC)

Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Circulating Tumor Cells

France, Germany, Belgium, United Kingdom
Massachusetts General Hospital

Recruiting

Culturally Aware AET Non-Initiation Intervention

Breast Cancer | Treatment Adherence | Survivorship | Treatment Refusal | Treatment Compliance

United States
SOLTI Breast Cancer Research Group

Terminated

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer (NEREA)

Breast Cancer

Spain, Portugal
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Puma Biotechnology, Inc.

Not yet recruiting

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Invasive Breast Lobular Carcinoma | Anatomic Stage I Breast Cancer | Anatomic Stage II Breast Cancer | Anatomic Stage III Breast Cancer

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Withdrawn

Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer Patients

Local Recurrence of Malignant Tumor of Breast
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery

Breast Cancer

United States
AM-Pharma

Withdrawn

A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis (LIST)

Bacteremia | Staphylococcal Infections

Netherlands
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

Advanced Breast Cancer

China
Ain Shams University

Completed

Early Versus Late Lactoferrin in Prevention of Neonatal Sepsis

Neonatal Sepsis
Institut Bergonié
Institut du Cancer de Montpellier - Val d'Aurelle; UNICANCER

Active, not recruiting

Survival Endpoints for Treatment Evaluation in Subjects Treated for Metastatic Breast Cancer: Contribution of Real-life Databases

Cancer

France
Novartis Pharmaceuticals

Withdrawn

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer (EarLEE-2)

Breast Cancer
Puma Biotechnology, Inc.

Not yet recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)

Metastatic Breast Cancer | Recurrent Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer

United States
Novartis Pharmaceuticals

Completed

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer (EarLEE-1)

Breast Cancer

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

HR Positive/HER2 Low Expression Metastatic Breast Cancer

China
Zhejiang Cancer Hospital

Recruiting

Dynamic Contrast-enhanced MRI Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver MBC (DreaminLMBC)

Metastatic Breast Cancer in the Liver

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC

Hormone Receptor Positive Advanced Breast Cancer

China
George Washington University

Completed

Taking Action to Thrive - A Healthy Lifestyle Intervention Pilot Study (THRIVE)

Overweight, Obesity and Other Hyperalimentation

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Safeway Foundation

Recruiting

Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC

Breast Cancer

United States
Massachusetts General Hospital

Completed

Endocrinology Auto-Triggered e-Consults

Diabetes Mellitus

United States
Zhejiang Cancer Hospital
307 Hospital of PLA; Fudan University; Hangzhou Cancer Hospital; Zhejiang University and other collaborators

Unknown

A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)

Breast Cancer

China
Jonsson Comprehensive Cancer Center

Recruiting

Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy (EXCALIBUR)

Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States

Search clinical trials for: Endocrine therapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations